Imiquimod (IMQ) is a synthetic ligand of toll-like receptor 7 that exerts antitumor activity and is already topically used in non-melanoma skin cancer and lentigo maligna melanoma in hard-to-treat areas, such as the face. The gene discussed is TLR7; the disease is melanoma.